I am Cheng-Li Lin, the Chief Biostatistician, with extensive leadership experience in clinical research infrastructure and advanced data analysis. My technical competencies include leading teams proficient in statistical software such as SAS, R, SPSS, and Stata. My core research contributions are guided by my role in Clinical Epidemiology and Drug Safety Evaluation, primarily leveraging the analysis of large-scale, Real-World Evidence (RWE) derived from nationwide data. Key Areas of My Published Research Include: Chronic Disease and Novel Drug Safety: Investigating the benefits and safety of novel glucose-lowering agents, such as SGLT-2 inhibitors, concerning overall mortality and cardiovascular risks in patients diagnosed with both cancer and diabetes mellitus. I also study the effect of anti-diabetic agents on severe complications like Interstitial Lung Disease. Cardio-Renal Outcomes and High-Impact Medications: Assessing the clinical impact of the heart failure drug sacubitril/valsartan in patients with End-Stage Renal Disease (ESRD) and heart failure. I conduct real-world comparisons of different Beta-blockers (e.g., nebivolol, carvedilol, and bisoprolol) in heart failure patients. Additionally, my work explores adverse short-term outcomes related to Acute Kidney Injury (AKI) co-existing with Chronic Kidney Disease (CKD) following atherosclerotic cardiovascular disease events in diabetic patients. Public Health and Neuro-Metabolic Intersections: Analyzing the associati